News Sentiment

PMCB sentiment intelligence

PharmaCyte Biotech Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 48 Balanced news tone 51 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.70 Week of 10 Jul 2026
Weighted tone 48/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

83/100 classification confidence.

Company focus 43

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-2.6% over one week, -8.5% over four weeks, trend inactive, and below fair value.

Latest direct headline Negative

PharmaCyte Biotech (PMCB) Holds Near Support as Modest Decline Tests Trader Conviction - Gap Down Bounce Plays

Market Reaction

Balanced read

61/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 83/100 classification
One-week reaction -2.6% Price reacting lower
Trend fit Trend inactive -8.5% over four weeks
Fair value -54.5% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 6
Neutral 37
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 43
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 11
TradingKey 9
TradingView 6
Market source 5
dars.gov.et 4
Moomoo 2
Intellectia AI 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 13
Regulatory and legal 3
Capital return 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 51
Moomoo Direct company coverage

PharmaCyte Biotech | DEF 14A: Definitive information statements

This document from PharmaCyte Biotech is a DEF 14A filing, which provides definitive information statements. These filings are submitted to the SEC by companies prior to a shareholder meeting to provide shareholders with information regarding matters to be voted upon. It likely c

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 20:40
Source
Moomoo
Moomoo Direct company coverage

PharmaCyte Biotech | SCHEDULE 13G: Others

This article provides details of a Schedule 13G filing for PharmaCyte Biotech. Schedule 13G filings are typically used by passive investors who own between 5-20% of a company's stock, indicating significant ownership without intending to influence control.

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 18:09
Source
Moomoo
TradingView Direct company coverage

Price to book forward of PharmaCyte Biotech, Inc. – NASDAQ:PMCB

This article provides the "Price to book forward" for PharmaCyte Biotech, Inc. (NASDAQ:PMCB), as listed on TradingView. It appears to be a financial data snippet rather than an in-depth analysis. The stock market for PMCB is currently closed with no trades.

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 04:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of PharmaCyte Biotech, Inc. – NASDAQ:PMCB

The article displays the "Price to sales forward" metric for PharmaCyte Biotech, Inc. (NASDAQ: PMCB) on TradingView. It appears to be a financial data point for the company, accessible through the platform's market analysis tools. The content includes navigation and footer elemen

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 20:09
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of PharmaCyte Biotech, Inc. – NASDAQ:PMCB

The article lists the "Price to earnings forward" for PharmaCyte Biotech, Inc. (NASDAQ: PMCB). It appears to be a financial data entry on a trading platform, indicating the value and change of this financial metric, likely for a specific period.

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 10:10
Source
TradingView
TradingKey Direct company coverage

PharmaCyte Biotech Inc (PMCB) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for PharmaCyte Biotech Inc (PMCB), indicating a current risk score of 1.34 and ranking 305 out of 386 in its industry. The company's beta of 0.50 suggests it is less volatile than the overall market. The assessment includes various metrics

Tone
Negative 30/100
Event
Market update
Published
19 Jun 2026 07:10
Source
TradingKey
TradingKey Direct company coverage

PharmaCyte Biotech Inc (PMCB) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of PharmaCyte Biotech Inc (PMCB), including a breakdown of major individual and institutional holders as well as different shareholder types. It lists top individual holders like Joshua Silverman and institutional investors such as C

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 07:39
Source
TradingKey
TradingKey Direct company coverage

PharmaCyte Biotech Inc (PMCB) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial health analysis of PharmaCyte Biotech Inc (PMCB), noting its current financial score of 6.98, which ranks 172 out of 389 in the Biotechnology & Medical Research industry. The company's financial status is described as robust, though its operating

Tone
Negative 39/100
Event
Market update
Published
17 Jun 2026 23:10
Source
TradingKey
TradingKey Direct company coverage

PharmaCyte Biotech Inc (PMCB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article for PharmaCyte Biotech Inc (PMCB) on TradingKey discusses the company's revenue breakdown. However, it states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The page provides gener

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 21:39
Source
TradingKey
TradingKey Direct company coverage

PharmaCyte Biotech Inc (PMCB) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of PharmaCyte Biotech Inc (PMCB) focusing on its dividend and stock split history. It indicates that the company has distributed $0.00 in dividends over the past five years and has no historical stock split data. The current stock price, market c

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 21:39
Source
TradingKey
TradingKey Direct company coverage

PharmaCyte Biotech Inc (PMCB) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of PharmaCyte Biotech Inc (PMCB), outlining its current price momentum, support and resistance levels, and signals from various technical indicators and moving averages. As of June 17, 2026, PMCB's price momentum score is 6.86, trading b

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 22:40
Source
TradingKey
TradingKey Direct company coverage

PharmaCyte Biotech Inc (PMCB) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for PharmaCyte Biotech Inc (PMCB), indicating that no earnings forecast score is currently available for the company. It notes that the Biotechnology & Medical Research industry's average score is 8.13. The company has not yet disclosed

Tone
Neutral 50/100
Event
Earnings
Published
16 Jun 2026 22:40
Source
TradingKey
TradingKey Direct company coverage

PharmaCyte Biotech Inc (PMCB) Institutional Confidence

PharmaCyte Biotech Inc (PMCB) has an institutional shareholding score of 3.00, placing it 193 out of 388 in the Biotechnology & Medical Research industry. The institutional shareholding proportion recently increased by 132.81% quarter-over-quarter, reaching 9.99%. James Simons is

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 10:39
Source
TradingKey
Simply Wall Street Direct company coverage

PharmaCyte Biotech (Nasdaq:PMCB) - Stock Analysis

This extensive stock analysis of PharmaCyte Biotech (Nasdaq: PMCB) provides an overview of the company's financials, performance, and recent news. The biotechnology company, focused on developing cellular therapies for cancer, currently has a small market cap of US$8.2m and no re

Tone
Negative 39/100
Event
Market update
Published
15 Jun 2026 09:10
Source
Simply Wall Street
Intellectia AI Direct company coverage

PMCB Technical Analysis & Stock Price Forecast

This article provides a technical analysis and stock price forecast for PharmaCyte Biotech Inc (PMCB), concluding with a "Strong Sell" consensus based on various technical indicators and moving averages. While some oscillators like the Stochastic Oscillator show buy signals, key

Tone
Negative 14/100
Event
Guidance
Published
08 Jun 2026 06:40
Source
Intellectia AI
Finviz Direct company coverage

PMCB - PharmaCyte Biotech Inc Stock Price and Quote

This page provides a detailed overview of PharmaCyte Biotech Inc. (PMCB) stock, including its current price, market performance, financial metrics, and recent news. It also lists key insider transactions and provides company information, highlighting its focus on developing treat

Tone
Positive 63/100
Event
Market update
Published
26 May 2026 12:40
Source
Finviz
TradingKey Direct company coverage

TradingKey

This page displays market data for PharmaCyte Biotech Inc. (PMCB), including its current stock price, market capitalization, and recent performance. The platform, TradingKey, provides financial information, analysis tools, and market news, and offers disclaimers regarding investm

Tone
Positive 59/100
Event
Market update
Published
15 May 2026 10:39
Source
TradingKey
Stock Titan Direct company coverage

PMCB SEC Filings - Pharmacyte Biotech Inc 10-K, 10-Q, 8-K Forms

This page provides a comprehensive resource for Pharmacyte Biotech (PMCB) SEC filings, including 10-K, 10-Q, and 8-K forms, alongside AI-generated summaries and impact analyses. Recent filings cover topics such as a proposed reverse stock split, insider ownership updates with war

Tone
Neutral 50/100
Event
Market update
Published
24 Apr 2026 18:39
Source
Stock Titan
Stock Titan Direct company coverage

PharmaCyte Biotech (PMCB) director awarded 119,170 stock options at $0.67

PharmaCyte Biotech director Jonathan Schechter was granted 119,170 stock options with an exercise price of $0.67 and an expiration date of March 30, 2036. This award serves as compensation and vests fully at the company's next annual stockholder meeting, contingent on his continu

Tone
Neutral 50/100
Event
Market update
Published
08 Apr 2026 05:09
Source
Stock Titan